Academic/ScientificNeurology updates Neurology Update: Adjunctive cenobamate for uncontrolled focal epilepsy in adults: phase II trial results June 12, 2020 A double-blind, randomised, placebo-controlled phase II study of adjunctive cenobamate in adults with uncontrolled focal epilepsy showed high rates of total seizure-freedom over 12 weeks. Read full update here. Neurology Update: Adjunctive cenobamate for uncontrolled focal epilepsy in adults: phase II trial results was last modified: June 12th, 2020 by EditorShare this...FacebookTwitterLinkedin 0 comment previous post ERN-RND & EAN Joint Webinars on Neurorehabilitation next post EAN launches a Task Force on Gender and Diversity issues in Neurology You may also like COVID-19 in Parkinson’s disease: Report on prevalence and outcome October 1, 2020 SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis December 2, 2020 New EAN Scientific Panel Neuroscience/translational neurology December 1, 2019 Rare Disease Day: EAN February 29, 2020 Cytokine release syndrome‐associated encephalopathy in patients with COVID‐19 September 1, 2020 Breaking News: A systematic review of neurological manifestations of SARS‐CoV‐2 infection: the devil is hidden in the detail June 18, 2020 Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong October 1, 2020 Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study January 5, 2021 Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. May 6, 2020 COVID-19, de novo seizures, and epilepsy: a systematic review December 2, 2020 Leave a Comment Cancel ReplyYou need to be logged in to comment. Please login to MyEAN on top.